W.L. Gore put up a $10 million convertible note for ViaCyte and the Type I diabetes treatment they’re working on. Last year the companies inked a deal to work on the synthetic pancreas ViaCyte is developing. The San Diego-based company’s Encaptra device is designed to be seeded with stem cells engineered to become pancreatic cells and implanted under the skin. […]
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
Dance Biopharm raises $24m for inhaled insulin device
Privately-held Dance Biopharm said yesterday that it raised $24.5 million in a private equity round to help fund the development of its inhaled insulin product. SternAegis Ventures was the exclusive placement agent for the offering. Molex Ventures, an electronics company working with Dance to develop a connected insulin delivery device, contributed to the round. Get the full […]
GI Dynamics raises $5 million for diabetes/obesity device
Investors have agreed to buy $5 million worth of GI Dynamics’ (ASX:GID) common stock, representing 6.9 million shares. The Lexington, Mass.-based company said it will use the money to fund the continued development of its EndoBarrier device and for general working capital. EndoBarrier is a plastic gut sleeve designed to treat type 2 diabetes and obesity […]
SFC Fluidics wins $1.4m grant to develop dual-hormone patch pump
SFC Fluidics said today that it won a $1.4 million grant to support the development of a dual-hormone patch pump for people with diabetes. The company’s ePump system is designed to control the delivery of insulin and glucagon via a small patch pump. The technology will also feature a flow confirmation sensor to determine, in real-time, […]
MedAutonomic implants device to treat metabolic syndrome
MedAutonomic said today it has successfully implanted a brain neuromodulation device, the Phoenix, into the stomach wall of a human through an innovative digestive endoscopic procedure. Powered without a battery, the Phoenix sends signals to the limbic system to reset an imbalance in the autonomic nervous system to treat metabolic syndrome and functional diseases […]
Livongo touts first connected BP monitor
Consumer digital health company Livongo Health today announced the first cellular-enabled blood pressure monitoring system in the U.S. Cellular connectivity allows for easy checking and reporting from home, eliminating the so-called “white coat” syndrome that leads to unnecessary prescriptions for high blood pressure, the company said in a prepared statement. Nearly 65% of people already using Livongo […]
DarioHealth raises $10m in private offering
DarioHealth (NSDQ:DRIO) said today that it closed a private placement offering with institutional and private investors, bringing in roughly $10.3 million for the Israel-based company. As part of the private placement, DarioHealth issued 4,266,800 shares of common stock at 90¢ apiece and 1,806,923 shares of Series D convertible preferred stock at $3.60 apiece. The company also offered […]
GE, DARPA are taking on Type 2 diabetes with electricity
GE and DARPA are collaborating on a $2.9 million study of neuromodulation as a treatment for Type 2 diabetes. GE scientists have developed a novel, potentially breakthrough approach that could restore nerve signals to a healthy state using non-invasive devices that stimulate metabolic biosystems and produce drug-like effects, but with greater precision than traditional treatments, […]
FDA to review Regeneron’s Eylea for diabetic retinopathy
Regeneron Pharmaceuticals (NSDQ:REGN) said today that the FDA plans to review the supplemental biologics license application for Regeneron’s Eylea aflibercept injection for the treatment of diabetic retinopathy. The U.S. agency plans to make a decision about the blockbuster drug by May 13, 2019. Get the full story at our sister site, Drug Delivery Business News.
One Drop wirelessly connects to Apple Watch
One Drop said today that its wireless blood glucose monitoring system can now connect directly to Apple Watch, making it the first diabetes company’s system to do so. One Drop was also the first such company to launch a companion Apple Watch app, but until now, users had to manually log blood glucose, food, medication, and […]
Insulet promotes COO to corner office as CEO Sullivan sets retirement date
Insulet (NSDQ:PODD) announced this week that president & COO Shacey Petrovic will succeed CEO Patrick Sullivan after he retires at the end of the year. Petrovic plans to stay on as president of the Billerica, Mass.-based company. Sullivan will retire from Insulet’s board effective Jan. 1, 2019 and will hold a consulting role with the company […]